Article citationsMore>>

Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.

has been cited by the following article:

• TITLE: Symptomatic changes in postmenopause with different methods of hormonal therapy

  AUTHORS: Marcelino Hernández-Valencia, Nydia Cordova, Antonio Vargas, Lourdes Basurto, Renata Saucedo, Carlos Vargas, Miriam Ruiz, Leticia Manuel-Apolinar, Arturo Zárate

  KEYWORDS: hormonal therapy; transdermal estradiol; tibolone; oral estrogen; nasal estradiol; postmenopause

  JOURNAL NAME: Open Journal of Preventive Medicine, Vol.1 No.2, August 22, 2011

  ABSTRACT: Objective: The diversity of opinions on the adverse effects of medications used to treat postmenopausal symptoms has prompted the use of various routes and mechanisms of action that need to be explored because bioavailability of the medications can vary. In order to select the appropriate route of administration for hormonal therapy (HT), it is necessary to determine baseline therapeutic efficacy. Design: We designed a prospective, randomized study consisting of four groups of postmenopausal wo-men: group 1 received oral conjugated estrogens, group 2 received a synthethic steroid, group 3 received estradiol nasally in spray form, and group 4 used transdermal estradiol in the form of patches. Criteria used to evaluate effectiveness was the Greene scale, which evaluate six components. These criteria were applied to each patient before hormonal intervention and then each month for 6 months. Luteinizing hormone (LH), follicle stimulating horone (FSH) and estradiol concentration were determined by chemiluminescence. Student’s t-test was used for intra-group comparisons before and after treatment. Results: There was a significant decrease in the vasomotor and sexual component (p